Novartis AG's Omalizumab Shines in Third Phase 3 Hives Trial

New data from a late-stage study of Novartis/Genentech's omalizumab add further evidence to show that the drug is safe and effective as a treatment for a debilitating form of hives. The Swiss drug giant has now presented data from the final of three Phase III studies on the drug, which is already on the market for asthma as Xolair, assessing its use to treat chronic spontaneous urticaria, a chronic form of hives with limited approved treatment options.

Help employers find you! Check out all the jobs and post your resume.